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in any medium, provided the original work is properly cited.Objectives: Identification of people with lower (white-coat
effect) or higher (masked effect) blood pressure at home
compared to the clinic usually requires ambulatory or
home monitoring. This study assessed whether changes in
SBP with repeated measurement at a single clinic predict
subsequent differences between clinic and home
measurements.
Methods: This study used an observational cohort
design and included 220 individuals aged 35–84 years,
receiving treatment for hypertension, but whose SBP
was not controlled. The characteristics of change in
SBP over six clinic readings were defined as the SBP
drop, the slope and the quadratic coefficient using
polynomial regression modelling. The predictive
abilities of these characteristics for lower or higher
home SBP readings were investigated with logistic
regression and repeated operating characteristic
analysis.
Results: The single clinic SBP drop was predictive of the
white-coat effect with a sensitivity of 90%, specificity of
50%, positive predictive value of 56% and negative
predictive value of 88%. Predictive values for the
masked effect and those of the slope and quadratic
coefficient were slightly lower, but when the slope
and quadratic variables were combined, the sensitivity,
specificity, positive and negative predictive values for the
masked effect were improved to 91, 48, 24 and 97%,
respectively.
Conclusion: Characteristics obtainable from multiple SBP
measurements in a single clinic in patients with treated
hypertension appear to reasonably predict those unlikely to
have a large white-coat or masked effect, potentially
allowing better targeting of out-of-office monitoring in
routine clinical practice.
Keywords: home–clinic blood pressure difference,
hypertension, masked effect, sensitivity, specificity,
white-coat effect
Abbreviations: AUC, area under the curve; BP, blood
pressure; HBP, home blood pressure; NPV, negative
predictive value; PPV, positive predictive value; TASMINH2,
Telemonitoring and Self-management in the Control of
Hypertension 2Journal of HypertensionINTRODUCTIONH
ypertension is an important risk factor for cardio-
vascular disease [1], which is the major cause of
morbidity and mortality worldwide [2]. In those
with established hypertension, effective management
depends on accurate measurement of blood pressure in
order to target antihypertensive treatment appropriately
and avoid unnecessary treatment and healthcare costs [3].
This measurement usually takes place in the physician’s
office (or clinic) in a primary care setting. However, clinic
blood pressure measurements frequently under/overesti-
mate true blood pressure which may result in incorrect
classification and hence subsequent management [4,5].
Depending on the direction of the error, such deviations
can be defined as ‘white-coat’ or ‘masked’ effects [6,7].
Patientswith a significantwhite-coat effect have higher clinic
blood pressure than would be expected for the correspond-
ing ambulatory or homemonitoring and are therefore at risk
of over-treatment [6]. Conversely, patients with a significant
masked effect have higher blood pressures with home or
ambulatorymonitoring thanwould beexpected for the clinic
blood pressure and therefore can be under-treated [7],
thereby potentially leading to increased target organ damage
[8,9] and cardiovascular mortality [10,11].
Recent research suggests that the white-coat effect may
be reduced by taking a mean of multiple clinic bloodDOI:10.1097/HJH.0000000000000319
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Sheppard et al.pressure readings over a short space of time [12–15]. This
can be done manually or systematically, using an auto-
mated blood pressure monitor such as the BpTRU device
used here, which measures blood pressure six times [14].
For many patients, such multiple measurements result in a
reduction in blood pressure, up to 15/6mmHg [14,15],
reducing any white-coat effect. Recently, this method has
also been shown to reduce the proportion of patients
displaying a masked effect in the clinic [16].
We hypothesized that the characteristics of multiple
measurements of clinic blood pressure are related to the
home–clinic blood pressure difference, thus potentially
allowing targeting of out-of-office blood pressure monitor-
ing in patients with white-coat or masked effects significant
enough to influence management. We examined this hy-
pothesis using data from a trial in which both multiple clinic
and home blood pressure measurements were taken [17].
METHODS
An extended description of the methods used in this study
can be found in the supplemental digital content http://
links.lww.com/HJH/A385.
Population
This was an observational cohort study. Participants com-
prised individuals screened for inclusion in the Telemoni-
toring and Self-management in the Control of Hypertension
2 (TASMINH2) trial who were subsequently randomized to
undertake self-monitoring of blood pressure at home [17].
Participants were recruited from 24 general practices in the
West Midlands, UK, between March 2007 and May 2008,
following written informed consent. Inclusion criteria for
the trial were age 35–84 years, receiving treatment for
hypertension and blood pressure not controlled below
140/90mmHg at baseline. Patients randomized to the inter-
vention arm of the trial, with at least 4 days of home blood
pressure readings in the first month after randomization,
were included in the analysis.
Data collection
At baseline, and 6 and 12 months of follow-up, clinic blood
pressure was measured in a standardized fashion using a
validated [18] BpTRU BPM-100 blood pressure monitor
(BpTRUMedical Devices Inc., Coquitlam, British Columbia,
Canada). After participants had been seated for 5min of
rest, six blood pressure measurements were taken auto-
matically at 1-min intervals (choice of 1–5-min intervals), all
of which were recorded (i.e. including the first reading
which is usually discarded) [19,20] by a researcher who was
present throughout the measurement period. Patient demo-
graphics (age, sex and ethnicity) and details of previous
history of cardiovascular disease were obtained from the
patient or extracted from their medical records.
Home blood pressure was measured by patients them-
selves, using the Omron705IT (Omron Healthcare Europe,
Hoofddorp, the Netherlands). Patients were asked to
measure their blood pressure whilst seated, twice in the
morning at 5-min intervals, during the first week of each
month and over a 12-month period. All blood pressure data
were transmitted to the research team via an automated2172 www.jhypertension.commodem device (i-modem; Netmedical, De Meern, the
Netherlands).
No attempt was made to impute missing data. Those
patients with missing self-monitoring data were excluded
from the analysis. All data collection was approved by the
Sandwell and West Birmingham Local Research Ethics
Committee (reference; 05/Q2709/103).
Analysis
The focus of the analysis was on the characteristics of SBP,
rather than DBP, as this is considered to be more closely
associated with underlying cardiovascular disease risk
[21,22]. Descriptive statistics were used to describe the
mean [95% confidence intervals (CIs)] clinic SBP for each
of the six measurements taken using the BpTRU device.
Summary data are presented as means SD (or 95% CIs)
and percentages of the trial population [in the intervention
(self-monitoring) arm, unless otherwise stated].
Home blood pressure was measured over a period of up
to 7 days and mean home blood pressure was calculated
having discarded the first day’s readings in accordance with
recommendations (up to 12 readings) [23]. To calculate the
home–clinic difference, the first clinic blood pressure read-
ing (measured at baseline using BpTRU) was subtracted
from the mean home blood pressure (measured in the first
month after baseline measurement, prior to any changes in
antihypertensive medication). The first clinic reading was
used in order to maximize the white-coat or masked effects
under investigation.
We estimated the drop in SBP (sixth minus the first
reading) in each individual patient at baseline and gener-
ated coefficients to represent the slope (linear) and quad-
ratic (curve) components of this drop using polynomial
regression modelling. These ‘characteristics’ were chosen
because they represent a simple and straightforward
approach (BP drop) which would be easy to implement
in clinical practice and also a more complex model which
more accurately represents the trends observed previously
when blood pressure is measured repeatedly in a clinic
setting [15]. These clinic blood pressure characteristics were
plotted against the corresponding home–clinic difference
for each individual and the relationship between the two
was investigated using Pearson’s correlation coefficient.
The relationship between clinic SBP and white-coat and
masked effects was also examined. It was not possible to
study white-coat and masked hypertension because this
terminology conventionally refers to treatment-naive patie-
nts and all patients enrolled into the TASMINH2 trial had
uncontrolled treated hypertension, and therefore their
blood pressures did not straddle the diagnostic threshold.
Because there areno standarddefinitionsof thewhite-coat or
masked effect, the sample populationwas divided into three
groups on the basis of the degree of difference between
home and clinic blood pressure. An arbitrary range of group
boundarieswere examinedandone-wayanalysis of variance
(ANOVA) was used to identify a boundary combination for
the final analysis groups which provided the largest
between-group variation (different home–clinic differences
between white-coat, normal and masked effect groups)
relative to the smallest within-group variation (patients
within each group with similar home–clinic differences).Volume 32  Number 11  November 2014
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To test the impact of the assumptions made in the main
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sensitivity analyses were undertaken using Pearson’s cor-
relation coefficient. A second set of sensitivity analyses
examined the reliability of the definition of the white-coat
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tive boundary combinations for both conditions altered the
results. These sensitivity analyses are detailed in theE 1. Characteristics of those enrolled in the TASMINH2 trial and t
present analysis)
racteristic TASMINH2
ber of patients
(years)
% female) 26
n SD of baseline SBP (mmHg) 1
n SD of baseline DBP (mmHg)
n SD of readings 2–6 baseline SBP (mmHg)
n SD of readings 2–6 baseline DBP (mmHg)
icity
hite British 46
ck African-Caribbean
uth Asian 1
xed race
her/unknown
iovascular disease comorbidity
gina 3
ocardial infarction 1
ronary artery bypass graft 2
oke 2
ripheral vascular disease 1
art failure
ronic kidney disease 3
betes 3
2, Telemonitoring and Self-management in the Control of Hypertension 2.
al of Hypertension‘expanded methods’ in the supplemental digital content
http://links.lww.com/HJH/A385.
RESULTS
Of the 480 patients who enrolled in the trial and attended
follow-up, 234 (49%) were randomized to the intervention
arm (self-monitoring). Sufficient home monitoring blood
pressure data were available from 220 patients (94%)
(at least 4 days of readings within a week in the first
month after randomization) who were subsequently
included, as pre-specified for the primary analysis.
Demographic characteristics of those included in
the analysis were similar to those in the original trial
(Table 1). Mean age was 67 9 years and just over half
were female (53%). Most were of white ethnic origin (95%),
baseline clinic blood pressure was raised (150/85mmHg)
and comorbidities were uncommon.
The overall mean difference in SBP between the first
clinic reading taken and the mean home blood pressure in
the first month was 14 17mmHg (home–clinic differ-
ence). The clinic blood pressure drop, slope and quadratic
coefficients were all significantly associated with the
home–clinic difference (Fig. 1). In the sensitivity analyses,
this effect remained significant regardless of the population
studied, the estimate of home–clinic difference used or the
time point in the trial at which variables were compared
(supplemental digital content, Table S1, http://link-
s.lww.com/HJH/A385).
The mean blood pressure, home–clinic difference, clinic
blood pressure drop, slope and quadratic coefficients for
the ‘normal’, white-coat and masked effect groups are
detailed in the supplemental digital content (Table S2,
http://links.lww.com/HJH/A385). As expected, initial clinic
blood pressure readings were higher in the white-coat
effect group and overall clinic blood pressure decreasedhose who completed home monitoring (who were included in the
trial population Home-monitoring population
480 220
679 679
0 (53%) 117 (53%)
5117 15012
8515 858
1487 1487
843 843
1 (96.0%) 209 (95.0%)
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0 (2.1%) 4 (1.8%)
1 (0.2%) 1 (0.5%)
1 (0.2%) 1 (0.5%)
0 (6.3%) 14 (6.4%)
4 (2.9%) 7 (3.2%)
2 (4.7%) 11 (5.0%)
1 (4.6%) 12 (5.5%)
1 (2.3%) 4 (1.8%)
2 (0.4%) 2 (0.9%)
9 (8.1%) 13 (5.9%)
5 (7.3%) 18 (8.2%)
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FIGURE 1 Scatter plots showing the correlation between home–clinic SBP differ-
ence and the blood pressure drop, slope and quadratic coefficients of SBP
measurements in the clinic.
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2174 www.jhypertension.comacross the entire six readings (Fig. 2). However, this
decrease was more pronounced in the white-coat effect
group, and blunted in the masked effect group. The drop,
slope and quadratic coefficients of clinic SBP were predic-
tive of white-coat and masked effects with similar degrees
of accuracy (Table 2). A drop in clinic blood pressure of
more than 11mmHg was predictive of the white-coat effect175
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FIGURE 2 Mean ( 95% confidence intervals) SBP for each clinic reading in white-
coat, normal and masked effect groups. SBP1-6, clinic SBP readings 1–6. HBP,
mean home blood pressure95% confidence intervals; this differed between
each group (white-coat group: 138mmHg, 95% CI 137, 140mmHg; normal
group: 146mmHg, 95% CI 145, 147mmHg; masked group: 160mmHg, 95% CI
158, 161mmHg) because each was defined on the basis of the home–clinic blood
pressure difference.
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Predicting home blood pressure in the clinicwith a sensitivity of 90% (95% CI 82–95%), specificity of
50% (95% CI 41–59%), PPV of 56% (95% CI 48–65%) and
NPV of 88% (95% CI 78–94%) [area under the curve (AUC)
of 0.78, 95% CI 0.72–0.84]. Both the slope and quadratic
coefficients were less predictive, but when combined, the
predictive accuracy of these coefficients was comparable to
that of the blood pressure drop (Table 2). Comparable
predictive accuracy was identified for all predictors using
a range of different definitions for white-coat and masked
effects in the sensitivity analyses (Table 2).
The clinic blood pressure change (‘drop’) was also
predictive of the masked effect (a decrease in clinic blood
pressure of less than 19mmHg was predictive of a masked
effect with a sensitivity of 91% (95% CI 76–98%), specificity
of 40% (95% CI 33–47%), PPV of 21% (95% CI 15–29%)
and NPV of 96% (95% CI 89–99%); AUC 0.77 (95% CI
0.68–0.86). Studied as individual coefficients, both the
slope and quadratic coefficients had comparable predictive
values to that of the clinic blood pressure drop, but com-
bined, the specificity and PPVs of these coefficients were
improved (Table 2). These values were again robust to the
results in the sensitivity analyses.
DISCUSSION
Main findings
The study has found a significant relationship between the
characteristics of the change in repeated blood pressure
measurements during a single clinic visit and the difference
between clinic and repeated home blood pressure
measurement. It was possible to rule out a white-coat or
masked effect in a group of treated patients, thus allowing
appropriate targeting of treatment intensification on the
basis of clinic measurements in some patients, and the
potential need for out-of-office measurement in others.
Such estimations were possible using a simple calculation
(blood pressure drop between the first and sixth readings in
a single clinic visit) which could easily be incorporated into
routine clinical practice (see, for example, Box 1). Themore
complex analyses incorporating the slope and shape of the
blood pressure curves had no additional benefit for pre-
dicting the white-coat effect, but when combined, resulted
in a more specific test for the masked effect. Was this to be
considered a clinically useful improvement, the method-
ology needed to estimate these variables in clinical practice
could be developed into an algorithm and made available
online (see, for example, Box 2) or incorporated into
automated blood pressure monitors in a similar way to that
used in atrial fibrillation detection [24].
Strengths and limitations
This was a post-hoc analysis of data from the TASMINH2
trial [17] and so the results need to be interpreted with
caution. Patients were drawn from the primary care, but all
had previously poorly controlled blood pressure and had
agreed to participate in a trial which required them to
measure their own blood pressure which might limit gen-
eralizability. Despite this, data were robustly collected
using validated equipment and trained staff, hence it is
unlikely that the relationships found here are due to
measurement errors. Blood pressure was measured inJournal of Hypertension www.jhypertension.com 2175
Box 1 Mrs Webster (63 years old) has diagnosed hypertension and comes to
the clinic for a routine blood pressure check. The doctor measures her blood
pressure repeatedly six times at 1-min intervals and uses these readings to
calculate her mean blood pressure (mean of the 1st–3rd readings) and SBP
drop. MrsWebster has a mean blood pressure of 151/90mmHg and a SBP drop
of 9mmHg.
Does she need out-of-office monitoring?
No. Mrs Webster’s SBP drop is less than the 11mmHg threshold for a white-
coat effect, thus indicating that her blood pressure characteristics are normal
and can be accurately treated on the basis of clinic readings alone.
Sheppard et al.the clinic using a standardized protocol, which, in contrast
to previous studies [12–15], included a researcher being
present throughout the six blood pressure readings whilst
the patient sat silently. This contrast in procedures had no
obvious impact on the blood pressure measurements taken:
the mean drop in blood pressure in the present study
(13/4mmHg) was comparable with that seen in previous
work (15/6mmHg) [14,15].
White-coat and masked hypertension are defined on the
basis of the effect of out-of-office pressure differences on
the diagnostic threshold [6,25]. Rather than studying the
predictive abilities of clinic blood pressure characteristics
for these arbitrarily defined conditions, patients were
assessed for a white-coat or masked effect. This both
improved the power to detect an effect and was necessary
because the cohort were all receiving treatment at baseline
and did not contain an adequate range of patients with
blood pressure above and below the clinic threshold for
hypertension (140/90mmHg) [26]. It is therefore possible
that patients displaying a masked effect may have been
under-represented. Both the white-coat and masked effects
are important issues in the management of hypertension,
even in patients with a diagnosis of hypertension who are
already receiving treatment. Patients with a significant
white-coat effect may appear to be uncontrolled, thus
receiving additional unnecessary medication if treatment
decisions are based on clinic blood pressure measurements
alone. Those with a significant masked effect may not have
treatment optimized, despite having underlying uncon-
trolled blood pressure, due to clinic blood pressure appear-
ing to be normal or close to the hypertension threshold.
There is no widely accepted definition of white-coat or
masked effects. Patients were therefore defined as display-
ing normal blood pressure characteristics, white-coat or
masked effects objectively using statistically rigorous yet
necessarily arbitrary thresholds. The sensitivity analyses
conducted here demonstrate that altering these thresholds
did not materially affect the predictive abilities of clinic
blood pressure characteristics. Approximately, 42% ofBox 2Mr Rasdall (51 years old) has come to the clinic for his first routine health
check. The doctor measures his blood pressure repeatedly six times at 1-min
intervals and inputs these readings into a web-based calculator to estimate his
mean blood pressure (mean of the 1st–3rd readings) and the combined slope
and quadratic coefficient of his clinic blood pressure readings. The doctor finds
that Mr Rasdall has a mean blood pressure of 132/78mmHg and a combined
slope and quadratic coefficient of 1.5.
Does he need out-of-office monitoring?
Yes. Mr Rasdall’s combined slope and quadratic coefficient is above the 2.3
threshold for a masked effect, thus indicating that although his blood pressure
appears to be normal, he may have masked hypertension and therefore
requires out-of-office monitoring to confirm whether treatment is needed.
2176 www.jhypertension.compatients were observed to display a white-coat effect and
15% a masked effect. These proportions are similar to the
previously reported estimations of the prevalence of white-
coat (36–47%) [27,28] and masked hypertension (9–21%)
[16,28–30] in treated patients with the caveat that such
proportions vary depending on the population studied,
how blood pressure is measured and how each condition
is defined [31,32].
The study used data from the TASMINH2 trial [17] and
hence home blood pressures were used to define out-of-
office blood pressure. Arguably, this is less robust than
ambulatory blood pressure monitoring, which is con-
sidered the ‘gold standard’ measure of out-of-office blood
pressure [5], largely due to a greater evidence base linking
it with end-organ damage and cardiovascular outcomes
[33–38]. Despite this, home monitoring is accepted as a
reliable alternative when diagnosing white-coat and
masked hypertension [39], although it is possible that
masked effects due to nocturnal hypertension could have
been missed in the present study. Future research should
therefore test the hypotheses proposed here using both
home and ambulatory blood pressure monitoring.Relationship to other literature
Other groups have comparedmultiple clinic blood pressure
measurements with out-of-clinic blood pressure monitor-
ing, but the current study is novel in its consideration of the
drop, the slope and the shape of the change in blood
pressure with repeated measurement. Previous work has
shown that clinic blood pressure measurements taken with
the BpTRU device are comparable with ambulatory blood
pressure measurements in treated hypertensive patients
[12,13,15]. In one study, Godwin et al. [13] showed that,
in a treated and poorly controlled population, the mean of
multiple clinic blood pressures predicts true controlled SBP
(on the basis of ambulatory blood pressure monitoring)
with a PPV of 80–87% and NPV of 49–59% (depending on
the threshold used). However, this population had better
blood pressure control than in the present study with many
more results above and below the threshold for hyperten-
sion and so is not directly comparable. Further work should
compare the two approaches in an untreated population
being considered for diagnosis of hypertension and assess
whether they are complementary.Implications for clinical practice and future
research
The study is the first to consider how more detailed phe-
notyping of clinic blood pressure (measured using a simple
method routinely available in clinical practice) might be
used to reduce the need for additional more complicated
blood pressure investigations such as ambulatory blood
pressure monitoring. The ‘clinic blood pressure drop’ or the
more complex algorithm based on slope and curve of
multiple readings could be incorporated into a triaging tool
for more targeted use of out-of-office blood pressure
monitoring (see, for example, Boxes 1 and 2). This could
be utilized (as it has been here) in treated hypertensive
patients to optimize management. Future research should
consider whether the same algorithm could be applied toVolume 32  Number 11  November 2014
Predicting home blood pressure in the clinican untreated or controlled group in order to assess the need
for ambulatory blood pressure monitoring. The current
diagnostic algorithm recommended in the UK guidelines
[26] suggests that all patients with raised clinic blood pres-
sure should be referred for out-of-office monitoring, whilst
the European Society of Hypertension recommends out-
of-office monitoring when white-coat or masked hyperten-
sion is ‘suspected’, although it is not clear how one would
suspect them [40]. Whilst the UK guidelines should improve
the targeting of treatment to those without a white-coat
effect, there is currently no reliable method to identify the
masked effect [3,15]. Multiple clinic readings might fill this
gap, although with the caveat that they may not identify all
features from ambulatory monitoring such as nocturnal
hypertension.
More work is needed to establish the appropriate
thresholds for white-coat and masked hypertension using
this new method in untreated patients with raised clinic
pressure, those with normotension and those with appa-
rently controlled clinic blood pressure. Further research
could include evaluating the predictive abilities of multiple
clinic readings for white-coat and masked effects when less
than six readings are taken; whether the methodology
requires a specific device (the BpTRU); and whether refer-
ring patients for out-of-office blood pressure monitoring on
the basis of clinic blood pressure characteristics results in
more or less unnecessary referrals than those approaches
detailed in the new UK guidelines [26] and algorithms [41].
In conclusion, these data suggest, for the first time, that
the characteristics of SBP measured repeatedly in a single
clinic visit are predictive of clinical differences in blood
pressure between repeated home and clinic measurements.
ACKNOWLEDGEMENTS
The authors would like to thank the patients and practices
that took part in the original TASMINH2 study without
whom this work would not have been possible.
Contributors: J.S., R.H., F.D.R.H. and R.J.Mc.M. had the
original idea. J.S. undertook the analyses and wrote the first
draft with R.J.Mc.M. and R.H. All authors subsequently
refined the manuscript and approved the final version.
R.J.Mc.M. is the guarantor.
Sources of funding: This study presents independent
research commissioned by the National Institute for Health
Research (NIHR) under its Programme Grants for Applied
Research funding scheme (RP-PG-1209–10051). R.J.Mc.M.
holds an NIHR Professorship. J.S. was funded by the NIHR
Birmingham and Black Country Collaboration for Leader-
ship in Applied Health Research and Care during part of this
work, but now holds a Medical Research Council Strategic
Skills Postdoctoral Fellowship. B.W. is a NIHR Senior
Investigator and is supported by the NIHR UCL Hospitals
Biomedical Research Centre. The TASMINH2 trial was
funded by the UK Department of Health Policy Research
Programme and the National Coordinating Centre for
Research Capacity Development. The views and opinions
expressed are those of the authors and do not necessarily
reflect those of the NHS, NIHR, or the Department of
Health. All equipment used in the study was purchased
commercially.Journal of HypertensionConflicts of interest
The authors declare that they have no conflicts of interest.
REFERENCES
1. Prospective Studies Collaboration. Age-specific relevance of usual BP
to vascular mortality: a meta-analysis of individual data for one million
adults in 61 prospective studies. Lancet 2002; 360:1903–1913.
2. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Risk
Assessment CollaboratingGroup. Selectedmajor risk factors and global
and regional burden of disease. Lancet 2002; 360:1347–1360.
3. Lovibond K, Jowett S, Barton P, Caulfield M, Heneghan C, Hobbs FD,
et al. Cost-effectiveness of options for the diagnosis of high blood pre-
ssure in primary care: a modelling study. Lancet 2011; 378:1219–1230.
4. Jin Y, Bies R, Gastonguay MR, Stockbridge N, Gobburu J, Madabushi R.
Misclassification and discordance of measured blood pressure from
patient’s true blood pressure in current clinical practice: a clinical trial
simulation case study. J Pharmacokinet Pharmacodyn 2012; 39:283–
294.
5. Hodgkinson J, Mant J, Martin U, Guo B, Hobbs FD, Deeks JJ, et al.
Relative effectiveness of clinic and home blood pressure monitoring
compared with ambulatory blood pressure monitoring in diagnosis of
hypertension: systematic review. BMJ 2011; 342:d3621.
6. Pickering TG, Coats A, Mallion JM, Mancia G, Verdecchia P. Blood
Pressure Monitoring. Task force V: white-coat hypertension. Blood
Press Monit 1999; 4:333–341.
7. Pickering TG, Davidson K, Gerin W, Schwartz JE. Masked hyperten-
sion. Hypertension 2002; 40:795–796.
8. Liu JE, Roman MJ, Pini R, Schwartz JE, Pickering TG, Devereux RB.
Cardiac and arterial target organ damage in adults with elevated
ambulatory and normal office blood pressure. Ann Intern Med
1999; 131:564–572.
9. Sega R, Trocino G, Lanzarotti A, Carugo S, Cesana G, Schiavina R, et al.
Alterations of cardiac structure in patients with isolated office, ambu-
latory, or home hypertension: data from the general population (Press-
ione Arteriose Monitorate E Loro Associazioni [PAMELA] Study).
Circulation 2001; 104:1385–1392.
10. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of
mortality associated with selective and combined elevation in office,
home, and ambulatory blood pressure.Hypertension 2006; 47:846–853.
11. Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J,
et al. Prognosis of ‘masked’ hypertension and ‘white-coat’ hyperten-
sion detected by 24-h ambulatory blood pressure monitoring 10-year
follow-up from the Ohasama study. J Am Coll Cardiol 2005; 46:508–
515.
12. Beckett L, Godwin M. The BpTRU automatic blood pressure monitor
compared to 24 h ambulatory blood pressure monitoring in the assess-
ment of blood pressure in patients with hypertension. BMC Cardiovasc
Disord 2005; 5:18–24.
13. GodwinM, Birtwhistle R, Delva D, LamM, Casson I, MacDonald S, et al.
Manual and automated office measurements in relation to awake
ambulatory blood pressure monitoring. Fam Pract 2011; 28:110–117.
14. Myers MG. Automated blood pressure measurement in routine clinical
practice. Blood Press Monit 2006; 11:59–62.
15. Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Grant FC, et al.
Conventional versus automated measurement of blood pressure in
primary care patients with systolic hypertension: randomised parallel
design controlled trial. Br Med J 2011; 342:d286.
16. Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Kaczorowski J. The
conventional versus automated measurement of blood pressure in the
office (CAMBO) trial: masked hypertension substudy. J Hypertens 2012;
30:1937–1941.
17. McManus R, Mant J, Bray EP, Holder R, Jones MI, Greenfield S, et al.
Telemonitoring and self-management in the control of hypertension
(TASMINH2): a randomised controlled trial. Lancet 2010; 376:163–172.
18. Mattu GS, Heran BS, Wright JM. Overall accuracy of the BpTRU: an
automated electronic blood pressure device. Blood Press Monit 2004;
9:47–52.
19. Mattu GS, Perry TL, Wright JM. Comparison of the oscillometric blood
pressure monitor (BPM-100beta) with the auscultatory mercury sphyg-
momanometer. Blood Press Monit 2001; 6:153–159.
20. Wright JM, Mattu GS, Perry TL, Gelfer ME, Strange KD, Zorn A, et al.
Validation of a new algorithm for the BPM-100 electronic oscillometric
office blood pressure monitor. Blood Press Monit 2001; 6:161–165.www.jhypertension.com 2177
Sheppard et al.21. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood
pressure and risk of coronary heart disease. The Framingham study.
Am J Cardiol 1971; 27:335–346.
22. Rutan GH, Kuller LH, Neaton JD, Wentworth DN, McDonald RH, Smith
WM. Mortality associated with diastolic hypertension and isolated
systolic hypertension amongmen screened for the Multiple Risk Factor
Intervention Trial. Circulation 1988; 77:504–514.
23. Stergiou GS, Parati G. The optimal schedule for self-monitoring of
blood pressure by patients at home. J Hypertens 2007; 25:1992–1997.
24. Wiesel J, Fitzig L, Herschman Y, Messineo FC. Detection of atrial
fibrillation using a modified microlife blood pressure monitor. Am J
Hypertens 2009; 22:848–852.
25. Pickering TG, Eguchi K, Kario K. Masked hypertension: a review.
Hypertens Res 2007; 30:479–488.
26. National Institute for Clinical Excellence. Hypertension: clinical man-
agement of primary hypertension in adults. Nice clinical guideline 127.
http://www.nice.org.uk/CG127. 2011.
27. MacDonald MB, Laing GP, Wilson MP, Wilson TW. Prevalence and
predictors of white-coat response in patients with treated hyperten-
sion. CMAJ 1999; 161:265–269.
28. Park SJ, Park JB, Choi DJ, YounHJ, Park CG, Ahn YK, et al.Detection of
masked hypertension and the ‘mask effect’ in patients with well
controlled office blood pressure. Circ J 2011; 75:357–365.
29. Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, et al.
Cardiovascular prognosis of ‘masked hypertension’ detected by blood
pressure self-measurement in elderly treated hypertensive patients.
JAMA 2004; 291:1342–1349.
30. Obara T, Ohkubo T, Kikuya M, Asayama K, Metoki H, Inoue R, et al.
Prevalence of masked uncontrolled and treated white-coat hyperten-
sion defined according to the average of morning and evening
home blood pressure value: from the Japan Home versus Office
Measurement Evaluation Study. Blood Press Monit 2005; 10:311–
316.
31. Verdecchia P, Schillaci G, Boldrini F, Zampi I, Porcellati C. Variability
between current definitions of ‘normal’ ambulatory blood pressure.
Implications in the assessment of white coat hypertension. Hyperten-
sion 1992; 20:555–562.
32. Powers BJ, Olsen MK, Smith VA, Woolson RF, Bosworth HB, Oddone
EZ. Measuring blood pressure for decision making and quality report-2178 www.jhypertension.coming: where and how many measures? Ann Intern Med 2011; 154:781–
788.
33. Fagard RH, Staessen JA, Thijs L. Prediction of cardiac structure and
function by repeated clinic and ambulatory blood pressure. Hyperten-
sion 1997; 29:22–29.
34. Imai Y, Ohkubo T, Sakuma M, Tsuji I, Satoh H, Nagai K. Predictive
power of screening blood pressure, ambulatory blood pressure and
blood pressure measured at home for overall and cardiovascular
mortality: a prospective observation in a cohort from Ohasama, north-
ern Japan. Blood Press Monit 1996; 1:251–254.
35. Mancia G, Zanchetti A, Gabiti-Rosei E, Benemio G, De GR, Forgari R.
Ambulatory blood pressure is superior to clinic blood pressure in
predicting treatment-induced regression of left ventricular hypertro-
phy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood
Pressure and Lisinopril Evaluation. Circulation 1997; 95:1464–1470.
36. Ohkubo T, Hozawa A, Nagai K, Kikuya M, Tsuji I, Ito S. Prediction of
stroke by ambulatory blood pressure monitoring versus screening
blood pressure measurements in a general population: the Ohasama
study. J Hypertens 2000; 18:847–854.
37. Staessen JA, Thijs L, Fagard R, O’Brien E, Clement D, de Leeuw P.
Predicting cardiovascular risk using conventional vs. ambulatory blood
pressure in older patients with systolic hypertension. Systolic Hyper-
tension in Europe Trial Investigators. JAMA 1999; 282:539–546.
38. Verdecchia P, O’Brien E, Pickering T, Staessen JA, Parati G, Myers M, et
al.When can the practicing physician suspect white coat hypertension?
Statement from the Working Group on Blood Pressure Monitoring of
the European Society of Hypertension. Am J Hypertens 2003; 16:87–91.
39. Nasothimiou EG, Tzamouranis D, Rarra V, Roussias LG, Stergiou GS,
Nasothimiou EG, et al. Diagnostic accuracy of home vs. ambulatory
blood pressure monitoring in untreated and treated hypertension.
Hypertens Res 2012; 35:750–755.
40. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, BohmM, et al.
2013ESH/ESCGuidelines for themanagement of arterial hypertension:
The Task Force for the management of arterial hypertension of the
European Society of Hypertension (ESH) and of the European Society
of Cardiology (ESC). Eur Heart J 2013; 34:2159–2219.
41. Myers MG. A proposed algorithm for diagnosing hypertension using
automated office blood pressure measurement. J Hypertens 2010;
28:703–708.Reviewer’s Summary Evaluation
Reviewer 1
Analysis of multiple clinic pressures device is compared
with home blood pressuremonitoring to arrive at predictors
for deciding whether home monitoring will be helpful.
Participants were part of the TASMINH2 trial and already
on treatment. The question is whether six clinic pressurescan accurately predict either the White Coat Effect or
Masked Hypertension, so that home monitoring can be
restricted to a targeted population. Clearly, additional stud-
ies of this issue are needed, but this report has important
implications for management (i.e. home monitoring, yes or
no) and especially for environments where home monitor-
ing is impractical, yet the estimating White Coat effect or
Masked Hypertension effect is needed.Volume 32  Number 11  November 2014
